Payment overview · 2025
General Payments
$214.48
12 reported records · 6 companies
Healthcare provider profile · identity verified
Kimberly M Franklin, MD
Allopathic & Osteopathic Physicians|Family Medicine · GREENWOOD, IN · NPI 1831172949
Verified facts
What the public records show
CMS Open Payments records show Kimberly M Franklin, MD received $214.48 in general payments during 2025 across 12 reported records.
Astellas Pharma US Inc accounted for 42.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $91.82 | 42.8% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $40.97 | 19.1% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.81 | 18.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.32 | 7.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.97 | 6.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.59 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $214.48 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $91.82 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $40.97 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $38.81 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 717 | 210 |
| Levothyroxine Sodium | Levothyroxine Sodium | 480 | 125 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 373 | 56 |
| Omeprazole | Omeprazole | 287 | 86 |
| Lisinopril | Lisinopril | 273 | 84 |
| Losartan Potassium | Losartan Potassium | 243 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 242 | 75 |
| Gabapentin | Gabapentin | 222 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 190 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 158 | 50 |
| Metformin Hcl | Metformin Hcl | 154 | 45 |
| Alendronate Sodium | Alendronate Sodium | 146 | 44 |
| Sertraline Hcl | Sertraline Hcl | 144 | 40 |
| Alprazolam | Alprazolam | 139 | 21 |
| Trazodone Hcl | Trazodone Hcl | 127 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 119 | 36 |
| Montelukast Sodium | Montelukast Sodium | 119 | 43 |
| Simvastatin | Simvastatin | 115 | 34 |
| Bupropion Xl | Bupropion Hcl | 108 | 32 |
| Famotidine | Famotidine | 102 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 102 | 29 |
| Clonazepam | Clonazepam | 96 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 28 |
| Tramadol Hcl | Tramadol Hcl | 85 | 17 |
| Celecoxib | Celecoxib | 83 | 26 |
| Furosemide | Furosemide | 81 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 80 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 74 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 23 |
| Pregabalin | Pregabalin | 72 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 26 |
| Carvedilol | Carvedilol | 69 | 18 |
| Ezetimibe | Ezetimibe | 69 | 21 |
| Allopurinol | Allopurinol | 67 | 21 |
| Buspirone Hcl | Buspirone Hcl | 66 | 23 |
| Metformin Hcl Er | Metformin Hcl | 66 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 22 |
| Glipizide Er | Glipizide | 65 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 20 |
| Lorazepam | Lorazepam | 62 | suppressed |
| Mounjaro | Tirzepatide | 61 | 15 |
| Meloxicam | Meloxicam | 56 | 22 |
| Ozempic | Semaglutide | 56 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 12 |
| Glimepiride | Glimepiride | 47 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 45 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 13 |
| Potassium Chloride | Potassium Chloride | 40 | 15 |
| Jardiance | Empagliflozin | 39 | 15 |
| Topiramate | Topiramate | 39 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 11 |
| Eszopiclone | Eszopiclone | 37 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | 12 |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | 11 |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 15 |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Eliquis | Apixaban | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Prolia | Denosumab | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Zafirlukast | Zafirlukast | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 12 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Prednisone | Prednisone | 11 | 11 |
| Risperidone | Risperidone | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $214.48 · 12 records | Astellas Pharma US Inc | Auvelity, FANAPT, QULIPTA, REXULTI, UBRELVY, Veozah, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error